Mark L. Fuerst
Staff Correspondent
Study: 12 weeks therapy combination cures virtually all HCV patients
A shorter, triple DAA therapy combination is not superior to 12 weeks of sofosbuvir plus velpatasvir in chronic HCV patients, according to researchers.
HBV reactivation with direct acting antivirals for HCV is highly manageable
New study indicates early recognition of HBV-HCV co-infection can lead to prompt treatment of HBV reactivation.
Real-world DAA therapy shows gains in community setting
Physicians have a “good, effective, safe therapy available” for hepatitis C virus genotype 6 patients, says researcher.
Study: DAA all-oral combination successful in treating hepatitis C
Early data shows promise in “real-world” effectiveness.
DAA therapy effective in advanced liver disease in real-world study
All-oral sofosbuvir-based therapy proves a significant advance for hepatitis C virus patients.
DAAs do not increase risk of hepatic decompensation in HCV patients
Researchers say theirs is first national study with a large population to examine possible link.
DAAs aid treatment of hepatitis C patients with cancer
Direct-acting antiviral agents can be safely administered with chemotherapy in patients with hepatitis C virus, according to new research.
DAA treatment restricted for Canadian hepatitis C patients
Patients with hepatitis C virus (HCV) in Canada are limited in their access to direct-acting antiviral agents, according to researchers.
COPD patient education can aid compliance efforts
Patient education is the key to enhancing treatment of COPD and getting patients to adhere to their recommended regimen.
Open communication facilitates more effective COPD care
An open dialogue between primary care physicians and COPD patients can make a real difference.

Poll